Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Equity Average (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Equity Average for 5 consecutive years, with -$387.6 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 30.94% year-over-year to -$387.6 million; the TTM value through Mar 2026 reached -$387.6 million, down 30.94%, while the annual FY2025 figure was -$345.9 million, 111.97% down from the prior year.
  • Equity Average hit -$387.6 million in Q1 2026 for Phathom Pharmaceuticals, up from -$430.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $15.5 million in Q2 2022 and bottomed at -$430.4 million in Q4 2025.
  • Average Equity Average over 5 years is -$178.0 million, with a median of -$150.9 million recorded in 2024.
  • Year-over-year, Equity Average surged 99.48% in 2023 and then tumbled 243218.5% in 2024.
  • Phathom Pharmaceuticals' Equity Average stood at -$50.6 million in 2022, then increased by 10.57% to -$45.3 million in 2023, then tumbled by 386.78% to -$220.3 million in 2024, then plummeted by 95.31% to -$430.4 million in 2025, then increased by 9.94% to -$387.6 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at -$387.6 million, -$430.4 million, and -$414.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.